On October 16, 2025 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its secondary endpoint of overall survival (OS) for the treatment of patients with platinum-resistant recurrent ovarian cancer in all comers. The trial studied KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. As previously announced, KEYNOTE-B96 met its primary endpoint of progression-free survival (PFS) in patients with platinum-resistant recurrent ovarian cancer whose tumors express PD-L1 and in all comers, as well as its secondary endpoint of OS for patients whose tumors express PD-L1, at previous interim analyses. Findings from these prior analyses will be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the final analysis of the trial, the KEYTRUDA-based regimen demonstrated a statistically significant and clinically meaningful improvement in OS in all comers compared to placebo plus chemotherapy with or without bevacizumab. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified. Results from this final analysis will be presented at an upcoming medical meeting.

"The results from the KEYNOTE-B96 trial mark the first time ever that an immune checkpoint inhibitor-based regimen has demonstrated the potential to help all patients with platinum-resistant recurrent ovarian cancer," said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. "These women face a very poor prognosis with limited options for treatment, and this impactful news is a testament to our tireless commitment to exploring new options for patients with gynecologic cancers who face a critical unmet need."

KEYTRUDA is not approved to treat ovarian cancer (see selected KEYTRUDA indications in the U.S. below). LYNPARZA (olaparib), which is being jointly developed and commercialized by AstraZeneca and Merck, has three approved ovarian cancer indications in the U.S.: in first-line maintenance treatment of BRCA-mutated advanced ovarian cancer, following complete or partial response to first-line platinum-based chemotherapy; in first-line maintenance treatment of HRD-positive advanced ovarian cancer in combination with bevacizumab, following complete or partial response to first-line platinum-based chemotherapy; and in maintenance treatment of BRCA-mutated recurrent ovarian cancer, following complete or partial response to platinum-based chemotherapy. For each of these indications, patients are selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA (see indications for LYNPARZA below).

As announced, data from the REJOICE-Ovarian01 trial in collaboration with Daiichi Sankyo evaluating raludotatug deruxtecan (R-DXd) in patients with platinum-resistant, high-grade ovarian primary peritoneal or fallopian tube cancer will be presented at the ESMO (Free ESMO Whitepaper) Congress 2025. R-DXd was recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancers expressing CDH6 who have received prior treatment with bevacizumab, based in part on data from the REJOICE-Ovarian01 trial. R-DXd was discovered by Daiichi Sankyo and is being jointly developed by Daiichi Sankyo and Merck.

About KEYNOTE-B96/ENGOT-ov65
KEYNOTE-B96, also known as ENGOT-ov65, is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT05116189) sponsored by Merck and conducted in collaboration with the European Network for Gynecologic Oncology Trial (ENGOT) groups investigating KEYTRUDA in combination with chemotherapy (paclitaxel) with or without bevacizumab compared to placebo plus chemotherapy with or without bevacizumab for the treatment of platinum-resistant recurrent ovarian cancer. The primary endpoint is PFS, and OS is a key secondary endpoint. The trial enrolled approximately 643 patients who were randomized to receive either KEYTRUDA (400 mg intravenously every six weeks for approximately two years) plus paclitaxel with or without bevacizumab, or placebo plus paclitaxel with or without bevacizumab.

About platinum-resistant ovarian cancer
Ovarian cancer often begins in the fallopian tubes or on the outer surface of the ovaries. It is the eighth most commonly diagnosed cancer and the eighth leading cause of cancer death among women worldwide. Globally, there were more than 324,000 patients diagnosed with ovarian cancer and almost 207,000 deaths from the disease in 2022. In many regions, its incidence has been increasing, with estimates projecting a 42% increase in new cases worldwide by 2040. In the U.S., it is estimated there will be approximately 20,890 patients diagnosed with ovarian cancer and about 12,730 deaths from the disease in 2025.

The primary aim of first-line treatment is to delay disease progression for as long as possible with the intent to achieve long-term remission. Between 70% and 80% of patients diagnosed with advanced ovarian cancer will experience disease progression following standard treatment with platinum-based chemotherapy regimens. Approximately 25% of these patients develop resistance within six months of completing first-line platinum-based chemotherapy, and this is defined as primary platinum-resistant ovarian cancer. Prognosis is particularly poor for these patients and treatment options are limited.

(Press release, Merck & Co, OCT 16, 2025, View Source [SID1234656706])

On October 16, 2025 ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, reported its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the "License Agreement") with the National Research Council of Canada (NRC) to license the NRC’s proprietary nanobody-based CD22 binder pursuant to the terms and conditions of the License Agreement (the "License").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The licence gives ME Therapeutics exclusive commercial rights to the nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy, including in vivo CAR-T and myeloid CAR (CAR-M) approaches.

"As a Canadian-owned company, we are honoured to advance this home-grown nanobody asset as part of our in vivo CAR cell therapy program," said Salim Dhanji, CEO of ME Therapeutics. "This milestone strengthens our commitment to develop innovative immuno-oncology candidates, including next-generation CAR therapies that can reprogram immune cells in the tumour microenvironment using advanced nanobody technology. We look forward to working with partners to bring these potentially life-saving treatments to cancer patients with currently limited options."

CD22 expression is often maintained in relapsed B-cell cancers following CD19 CAR-T therapy. By leveraging nanobody technology, the NRC’s CD22 binder offers potential advantages in stability, synthesis, and design flexibility compared to traditional antibody formats. Through in vivo CAR-M and CAR-T approaches, the binder provides an opportunity for novel approaches to treat patients with relapsed/refractory disease or as part of a first-line treatment.

"We are pleased to license this Canadian-made, publicly-owned nanobody-based CD22 binder to a Canadian company for use in next-generation CAR applications," says Sue Twine, Director General of the NRC’s Human Health Therapeutics Research Centre. "This technology was developed through years of dedicated NRC research, with support from our Cell and Gene Therapy Challenge program. It is a compelling example of publicly funded research enabling innovative next generation tools that can support development of affordable, cutting-edge treatments for Canadian patients."

The nanobody-based CD22 binder is currently being evaluated as part of an autologous CAR-T therapy in an investigator-driven Phase 1 clinical trial (NCT06208735) to assess safety and efficacy in pediatric and adult patients.

The Licence has been granted to the Company pursuant to the terms of the Licence Agreement in Australia, Brazil, Canada, China, Europe, India, Israel, Japan, New Zealand, Singapore, South Korea, and the United States (collectively the "Territory") for applications of the technology in these regions within the authorized field of use, which is CAR therapy. The rights granted to the Company are exclusive within the field of use for autologous CAR cell therapy products in the Territory (except in Canada) and exclusive in all jurisdictions of the Territory for any CAR cell therapies other than autologous CAR cell therapy products. The Licence Agreement provides, among other things, that the Company may sub-license its rights under the License Agreement. In consideration for the grant of the Licence, the Company shall pay the NRC an upfront licence fee within 12 months of entry into the License Agreement, and shall pay the NRC the certain royalties as more particularly described in the License Agreement relating to the sale of autologous CAR cell therapy products and sales revenue from the sale of allogeneic or in-vivo CAR cell therapy products, in all cases subject to a minimum yearly royalty subject to the terms and conditions of the License Agreement. In addition, the Company has agreed to make certain milestone payments to the NRC for each product on initiation of dosing in Phase 1 Trials, on initiation of dosing in Phase 2 clinical trials, on initiation of dosing in a registration trial, and on six months after the first regulatory approval of the first product anywhere in the Territory. The Licence shall expire upon the expiry of the last claim of the last patent pursuant to the terms of the License Agreement.

(Press release, ME Therapeutics, OCT 16, 2025, View Source [SID1234656705])

On October 16, 2025 Iterion reported to present new data on Tegavivint at the upcoming AACR (Free AACR Whitepaper)–NCI–EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), October 22–25 in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our Chief Scientific Officer, Stephen Horrigan, and Senior Director of Translational Research and Non-Clinical Development, Aundrietta Duncan, will share findings highlighting Tegavivint’s first-in-class mechanism and activity in advanced hepatocellular carcinoma (aHCC).

Tegavivint, the most advanced Wnt/β-catenin inhibitor in clinical development, targets TBL1, leading to degradation of nuclear β-catenin and inhibition of Wnt-driven oncogenic transcription. This novel approach has shown excellent tolerability and encouraging clinical activity in an ongoing Phase 1/2 aHCC trial.

📍 Poster Details
Title: Activity of Tegavivint in Hepatocellular Carcinoma with Aberrant Wnt/β-catenin Signaling and Evaluation of Biomarker Response
Date & Time: Friday, October 24, 2025 | 12:30 – 4:00 PM
Session: Poster Session B
Poster #: B135

(Press release, Iterion Therapeutics, OCT 16, 2025, View Source [SID1234656703])

On October 16, 2025 I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, reported its new business model, focused on its global capabilities built to accelerate access to innovative medicines and to enable broad strategic growth. The Company announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company also announced the pending acquisition of VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) than current standard of care. The pending acquisition will be made by a newly formed subsidiary, Visara, Inc. (Visara), a clinical-stage biopharmaceutical company focused on developing ophthalmic therapeutics for serious eye disorders, and is expected to be completed later this month.

In addition, the Company reaffirmed its previously announced givastomig investment plans as part of its new strategy.

Mr. Kyler Lei has been named Chief Financial Officer (CFO) of I-Mab, bringing significant expertise in the Hong Kong and global capital markets.

The Company sees a significant growth potential from the Asia Pacific originated biopharma innovations. Confidence in this opportunity comes from emerging trends showing that the Asia Pacific region has generated more than 30% of global biopharma assets under development, and has achieved more than $80B in deal value through collaborations with leading multi-national pharmaceutical organizations. In addition, the Asia Pacific biopharmaceutical ecosystem has become increasingly agile and efficient, with significantly lower clinical trial costs and faster patient enrollment than the global median, while maintaining high quality standards1.

"We believe we are entering a new era of rapid growth in the global biotech economy, driven by greater innovation capability in China and Asia and a resurgence of investment in high growth international markets across Asia. With our new business model, we are uniquely positioned to strategically create significant value for patients and investors," said Mr. Fu Wei, Executive Chairman of I-Mab. "Through the strategic insight of our expanded Board, backing by CBC Group,

Asia’s largest dedicated healthcare asset management firm, and our dual listing strategy, I-Mab is ideally placed to partner with leading global innovators to identify and accelerate high-value assets. The proposed dual listing on both NASDAQ and HKEX is a key element of our global growth strategy. This move will enable us to broaden and diversify our investor base, and enhance trading liquidity and access to capital, while strengthening our presence with key stakeholders in the rapidly growing Asian market."

"2025 has been a time of significant progress for I-Mab. Presentation of compelling Phase 1b givastomig combination data reinforced our confidence in its potential to be a best-in-class Claudin 18.2-directed therapy for gastric cancer and drove our plans to initiate a global randomized Phase 2 study, expected to begin in Q1 2026. In addition, the Company recently secured additional capital, and has attracted seasoned biotech executives to the Board of Directors and Scientific Advisory Board," said Sean Fu, PhD, Chief Executive Officer (CEO) of I-Mab. "With the strong foundation from our work on givastomig, and excellent progress this year, we are optimistic about moving forward with our new strategy. Our new global platform allows us to uphold our commitment to value creation by realizing the full potential of innovative medicines and improving the lives of patients."

The NovaBridge Business Model and Pipeline

The Company intends to partner with leading innovators to identify and accelerate high-value assets. Our model integrates rigorous asset selection, bespoke translational strategies, and efficient clinical execution. With the backing of CBC Group, we leverage deep local insights and global capabilities to develop the most promising drug candidates across a range of therapeutic categories.

The Company will utilize a "hub-and-spoke" model to create and advance specialized subsidiary companies (spokes) which maintain operational focus and agility. By focusing each spoke on a specific asset or therapeutic area, the Company can optimally manage risk and create value through potential partnering transactions.

Pipeline:

•
Givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, is in Phase 1b clinical trials for the potential treatment of gastric cancer and other Claudin 18.2-positive gastrointestinal malignancies. A global, randomized Phase 2 study is planned, with the enrollment of the first patient targeted in Q1 2026. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.
•
Ragistomig is an anti-PD-L1 X 4-1BB bispecific antibody. Built on Phase 1 clinical data, an ongoing Phase 1b study designed to expand the therapeutic index is expected to yield results in 2H 2026. The program is being jointly developed with ABL Bio.
•
Uliledlimab targets CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. Progression free survival (PFS) data are expected in 2H 2026 from an ongoing randomized Phase 2 trial evaluating uliledlimab + toripalimab compared to pembrolizumab alone or toripalimab alone. I-Mab owns worldwide rights to uliledlimab outside of Greater China.
VIS-101, to be acquired by Visara, a newly formed I-Mab subsidiary, under the new business model, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development

•
VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet AMD, DME, and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in both the US and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.
•
Acquisition will be completed by a newly formed subsidiary, Visara. Visara, a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics, will be launched with an approximately $37M capital infusion from I-Mab and the contribution of certain rights by AffaMed Therapeutics (HK) Limited. The capital contributions to Visara and its acquisition of VS-101 (collectively, the Transactions) are cross-conditioned, and are expected to close later this month. The Company has also signed a separate termsheet with Everest Medicines (HKEX 1952.HK) to potentially out-license greater China rights for VIS-101 and collaborate on global clinical development. Following completion of the Transactions, I-Mab will be the majority shareholder of Visara, and Visara will control global rights to VS-101.
•
Visara is led by Co-Founder and Executive Chairman Emmett T. Cunningham, Jr., MD, PhD, MPH. Dr. Cunningham has been a physician, innovator, entrepreneur, and investor for more than 25 years, formerly serving as Senior Managing Director at Blackstone Group L.P. and Managing Director at Clarus Ventures, LLC. Dr. Cunningham is also an internationally recognized specialist in infectious and inflammatory eye disease with over 450 co-authored publications.
"VIS-101 is anticipated to be second-in-class with best-in-class potential, based on bioengineered, superior target neutralizing capabilities," said Dr. Cunningham, Co-Founder and Executive Chairman of Visara. "Leveraging the speed, quality, and unique advantages of dedicated teams in North America and Asia, Visara will seek accelerated global clinical development and regulatory approvals."

Organizational Overview

The Company will build on the strength of the I-Mab Board, led by Mr. Fu Wei, Executive Chairman, including the expanded Scientific Advisory Board and new Research and Development Committee. The Executive Leadership Team will include Sean Fu, PhD, Chief Executive Officer; Phillip Dennis, MD, PhD, Chief Medical Officer; Kyler Lei, Chief Financial Officer; and Claire Xu, MD, PhD, Senior Vice President, Clinical Development.

Kyler Lei has been appointed as the Chief Financial Officer of I-Mab, effective October 16, 2025. Kyler is a global capital markets and investor relations professional with extensive experience in healthcare, equity research, corporate communications, corporate finance and strategy. Kyler will be primarily responsible for overseeing overall financial strategy and management, corporate finance and capital markets, corporate development and operations. Prior to joining I-Mab, Kyler served as Deputy General Manager and Head of Capital Markets at Sino Biopharmaceutical Limited (HKEX: 1177.HK).

"I am enthusiastic about starting on this new chapter with Kyler, and leveraging his expertise in global capital markets and financial strategy to make our new business model a resounding success," said Dr. Fu, CEO.

Dr. Fu added, "I would like to extend our gratitude to Joseph Skelton for his tremendous contributions in shaping I-Mab’s success. We wish him all the best in his future endeavors."

Business Update Webinar

The Company will review its new business model, strategic focus and upcoming milestones by webcast on Thursday, October 16, 2025, and Friday, October 17, 2025

Webcast and Conference Call Details:

In English:

•
Date: Thursday, October 16, 2025
•
Time: 5:00 PM ET
•
Dial-in number (US): 1-877-407-0784
•
Dial-in number (International): 1-201-689-8560
•
Webcast info: please click here
In Chinese:

•
Date: Friday, October 17, 2025
•
Time: 5:00 PM HKT/5:00 AM ET

•
Webcast info: please click here, and note Kyler Lei as the CLSA contact
A replay of the webinar will be accessible on the Events page of the Company website for 90 days.

(Press release, I-Mab Biopharma, OCT 16, 2025, View Source [SID1234656702])

On October 16, 2025 EORTC reported it will be prominently featured at the EANO 2025 conference, held in Prague from 16 to 19 October. Our team will present seven scientific abstracts, including two oral presentations and five posters, highlighting ongoing research in neuro-oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, EORTC projects will be featured in a joint session with the Brain Tumour Group (BTG), where six participants will present on clinical trial planning and current case studies, highlighting the collaborative efforts within EORTC to advance cancer research.

Further details can be found in the table below.

EORTC ABSTRACTS
AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE
Ogechukwu Edeh-Asogwa, Netherlands Friday, 17 October 10:35 – 10:45
Type: Oral session
Room: Forum Hall
FINAL CLINICAL AND MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1P/19Q CODELETION
Martin Van Den Bent, Netherlands Saturday, 18 October 11:25 – 11:35
Type: Oral session
Room: Forum Hall
EANO, EORTC, EPTN and ESNR consensus-based definition for post-radiotherapy MRI abnormalities in the brain: preliminary findings from an interdisciplinary Delphi study
Maarten Lambrecht, Belgium Friday, 17 October 17:00 – 18:30
Type: Poster session
Room: Forum Hall Foyer 3
VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
Marjolein Geurts, Netherlands Friday, 17 October 18:00 – 19:30
Type: Poster session
Room: Forum Hall Foyer 3
MGMT METHYLATION DURING THE PROGRESSION OF GLIOBLASTOMA
Bo Deng, Netherlands Saturday, 18 October 17:00 – 18:30
Type: Poster session
Room: Forum Hall Foyer 3
THE USE OF EORTC QLQ-C30 SUMMARY SCORE IN CANCER CLINICAL TRIALS AND ITS PERFORMANCE AS COMPARED WITH THE GLOBAL HEALTH / QUALITY OF LIFE SCALE: A COMPARATIVE ANALYSIS OF EFFECT SIZES
Josien Scheepens, Netherlands Saturday, 18 October 17:00-18:30
Type: Poster session
Room: Forum Hall Foyer 3
ASSOCIATION BETWEEN TEMOZOLOMIDE-RELATED HEMATOLOGICAL TOXICITY AND HRQOL SCORES IN GLIOBLASTOMA: A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS
Clemens Seidel, Deutschland Sunday, 19 October 2025 12:00-12:45
Type: Poster session
Room: Forum Hall Foyer 3
SESSIONS
WHAT CAN A SUPPORTING AGENCY SUCH AS EORTC DO FOR YOU?
Michael Weller, Switzerland JOINT SESSION
Saturday, 18 October 08:00 – 08:14
South Hall 2
CLINICAL TRIAL MANAGEMENT: STEERING COMMITTEE, THE MEDICAL MONITOR AND THE DATA MONITORING COMMITTEE
Patrick Roth, Switzerland JOINT SESSION
Saturday, 18 October 08:14 – 08:28
South Hall 2
EORTC-2227 (LEGATO): LOMUSTINE WITH AND WITHOUT REIRRADIATION FOR FIRST PROGRESSION OF GLIOBLASTOMA: A RANDOMIZED PHASE III STUDY
Tomas Kazda, Czech Republic JOINT SESSION
Saturday, 18 October 08:28 – 08:36
South Hall 2
EORTC-2334 (LUMEN-1): 177LU-DOTATATE FOR RECURRENT MENINGIOMA: A RANDOMIZED PHASE II STUDY
Emeline Tabouret, France JOINT SESSION
Saturday, 18 October 08:36 – 08:44
South Hall 2
EORTC 2427 (VIGOR): VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2 OR 3 ASTROCYTOMA: A PLACEBO-CONTROLLED RANDOMIZED PHASE III STUDY
Marta Padovan, Italy JOINT SESSION
Saturday, 18 October 08:44 – 08:52
South Hall 2
EORTC-2013 (GLIO-RARE): OBSERVATIONAL STUDY FOR ASSESSING TREATMENT AND OUTCOME OF PATIENTS WITH PRIMARY BRAIN TUMOURS DIAGNOSED ACCORDING TO CIMPACT-NOW RECOMMENDATIONS AND THE 2021 WHO CLASSIFICATION
Maximilian Mair, Austria JOINT SESSION
Saturday, 18 October 08:52 – 09:00
South Hall 2

(Press release, EORTC, OCT 16, 2025, View Source [SID1234656701])